Full-Time

Associate Director

Computational Biology

Posted on 5/12/2026

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

Compensation Overview

$180.5k - $240k/yr

Silver Spring, MD, USA

Hybrid

Requires reporting to the Silver Spring office at least four days/week; in-office days may increase.

Category
Biology & Biotech (1)
Required Skills
Python
R
Julia
MATLAB
Requirements
  • Doctor of Philosophy (PhD) in engineering, applied mathematics, systems biology, or related field of study
  • 7+ years of experience in mechanistic modeling approaches in the pharmaceutical industry
  • Experience leading, developing, and mentoring team members, with demonstrated ability to build capability and support professional growth
  • Experience with common databases and tools relevant to bioinformatics and systems biology
  • Expertise in a variety of modeling formalisms for systems biology (e.g., differential equation, logic-based, or agent-based models)
  • Expertise in pharmaceutical modeling and simulation approaches (e.g., quantitative systems pharmacology (QSP) or physiologically-based pharmacokinetic (PBPK) modeling)
  • Advanced knowledge of numerical methods relevant to modeling and simulation, including solving systems of ordinary and/or partial differential equations, optimization, Monte Carlo methods
  • Fluency in one or more scientific programming languages (e.g., Python, R, Julia, and/or MATLAB)
  • Knowledge of molecular and cellular biology and drug development
  • Experience communicating effectively with both technical and non-technical audiences as demonstrated by record of presentations and publications
Responsibilities
  • Lead teams in strategically planning and implementing mechanistic models of molecular and cellular processes in the lung, including but not limited to regulation of vasoconstriction and bronchoconstriction, response to hypoxia, toxicity to airways/alveoli, and initiation/resolution of inflammation and fibrosis
  • Provide expertise in evaluating innovative approaches for mechanistic modeling, informing technical direction and prioritization for areas such as AI-enabled model development, multiscale coupling, in silico trials, and regenerative medicine
  • Define, evolve, and execute a technical strategy in partnership with other internal subject matter experts to apply model-informed drug development throughout the company
  • Build and manage collaborations with external partners to generate data for model training/validation
  • Coordinate teams of computational biologists and engineers to build HPC workflows for multiscale models that bridge organ physiology with cell- and molecular-level processes
  • Advance company-wide uptake of computational modeling by leading development of simulation tools and interfaces in partnership with leaders in other R&D departments
  • Communicate results through presentations at internal and external meetings, and peer-reviewed publications
  • Direct and manage team to include responsibilities for goal setting, performance reviews/management, coaching, mentoring and career development
  • All other duties as assigned
Desired Qualifications
  • Experience processing and analyzing large-scale genomic and transcriptomic datasets
  • Strong data visualization skills, including interactive visualization (e.g. R Shiny or d3.js)
  • Skilled in statistical and machine learning methods
  • Knowledge of pulmonary physiology
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Simplify Jobs

Simplify's Take

What believers are saying

  • Ralinepag Phase 3 triples PAH efficacy, doubles patient base to 30,000 in two years.
  • Tyvaso IPF TETON trials show 100mL lung function gain, NEJM published.
  • $2B share repurchase deploys $1.5B by March 2026 amid $3.8B cash.

What critics are saying

  • Nebulized Tyvaso sales drop 22% YoY as DPI cannibalizes core revenue.
  • Remodulin sales fall 8% YoY from newer PAH competitor pressure.
  • Ralinepag DPI hinges on MannKind; delays collapse PAH expansion.

What makes United Therapeutics Corporation unique

  • United Therapeutics pioneered public benefit corporation structure in 2021 for biotech.
  • Leads xenotransplantation via Revivicor subsidiary engineering donor pigs.
  • Partners with Varda for microgravity drug manufacturing in orbit.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at United Therapeutics Corporation who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Yahoo Finance
Mar 19th, 2026
The Trade Desk and United Therapeutics emerge as mid-cap growth picks while Builders FirstSource stumbles

Here is a summary of the article: Investment analysis platform StockStory has identified two mid-cap stocks worth buying and one to avoid. The Trade Desk, a cloud-based advertising platform, trades at $23.53 per share with a market capitalisation of $11.21 billion. The company posted 22% annual revenue growth over the past two years and boasts a 20.3% operating margin. United Therapeutics, which develops treatments for chronic lung diseases, has a market capitalisation of $23.24 billion. The company achieved 16.9% annual revenue growth over two years whilst demonstrating strong free cash flow generation and improving returns on capital. StockStory advises avoiding Builders FirstSource, a construction materials manufacturer. The company experienced 5.7% annual sales declines over the past two years, with eroding returns on capital and declining earnings per share.

Yahoo Finance
Mar 14th, 2026
United Therapeutics publishes Tyvaso IPF data in NEJM, eyes first inhaled anti-fibrotic approval

United Therapeutics has published full Phase 3 TETON-2 trial data for nebulised Tyvaso in idiopathic pulmonary fibrosis in the New England Journal of Medicine. The study demonstrated preservation of lung function and reduced clinical worsening in IPF patients. If approved by the FDA, Tyvaso would become the first and only inhaled anti-fibrotic treatment for IPF, significantly expanding United Therapeutics' addressable market. The company's shares currently trade at $536.12, with one-year returns of 74.5%. The publication in a top-tier journal represents a significant milestone for the drug developer. Investors are now monitoring potential FDA review milestones and how IPF could influence revenue beyond the current $3.2 billion base, though regulatory or reimbursement challenges remain key risks.

Yahoo Finance
Feb 26th, 2026
United Therapeutics shares drop 7.2% on $790M revenue miss despite earnings beat

United Therapeutics shares fell 7.2% after the biotechnology company reported fourth-quarter revenue of $790.2 million, missing analysts' consensus estimates of over $805 million. Whilst revenue grew 7% year-over-year, Tyvaso sales, though up 12%, also fell short of projections. The company did beat earnings expectations with adjusted earnings of $7.70 per share versus the forecasted $7.10. However, the revenue miss overshadowed the earnings beat, prompting negative market reaction. The stock has shown relatively low volatility over the past year, with only eight moves greater than 5%. United Therapeutics is currently trading at $500.08 per share, near its 52-week high of $535.10. Shares are flat year-to-date.

Yahoo Finance
Feb 26th, 2026
United Therapeutics targets 2026 soft-mist inhaler launch, surpasses $3B in annual revenue

United Therapeutics reported fourth-quarter 2025 results, with full-year revenue surpassing $3 billion for the first time, representing 11% growth. Fourth-quarter revenue reached $790 million, whilst Tyvaso generated $464 million with dry-powder inhaler sales growing 24% year-over-year. The company plans to file its soft-mist treprostinil inhaler, Tresmi, for approval this year, targeting a 2026 commercial launch. Early studies suggest the device could reduce coughing by up to 90% compared to dry-powder alternatives. Near-term catalysts include a once-daily "super prostacyclin" readout next week and TETON-1 IPF trial results next month, with potential launch by June 2027. The company's Zeno xenotransplant programme has transplanted two patients, targeting a commercial product by 2030.

Yahoo Finance
Feb 25th, 2026
United Therapeutics misses Q4 revenue estimates despite 7.4% growth to $790M

United Therapeutics missed Wall Street's revenue expectations in Q4 2025, reporting $790.2 million against estimates of $810.4 million, though sales rose 7.4% year on year. The biotechnology company's GAAP profit of $7.70 per share beat analyst estimates by 14%. The company, which develops treatments for chronic lung diseases and pulmonary hypertension, has demonstrated solid long-term performance with 16.5% annualised revenue growth over five years. However, its operating margin declined to 45.1% from 48.6% in the prior-year quarter. Analysts expect revenue to remain flat over the next 12 months, representing a deceleration from recent growth rates. United Therapeutics has a market capitalisation of $20.38 billion.